🟢 ELTX is trading 16.85% up today as it rebounds from ELI-002 pancreatic cancer data selloff

ELTX is trading at $4.57 (+16.85%) as buyers step back in following a sharp decline linked to recent clinical trial results.

• The stock is seeing a volatile rebound after a collapse triggered by the ELI-002 7P pancreatic cancer study missing its primary endpoint.
• Market observers characterize the move as a short-covering rally in a thin biotech name rather than a macro-driven shift.
• The upward move occurs against a backdrop of a softer broader market, with major U.S. indices trading lower today.